Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.270 +0.290 (+4.85%)
Streaming Delayed Price Updated: 3:11 PM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. Common Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Study Discovers Mechanisms Behind Relapse After Treatment of MDD
Via Investor Brand Network
Study Indicates People Are Cautious About Psilocybin Therapy, More Awareness Needed
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
From Cybin Inc.
Via Business Wire
Research Finds That Mushrooms May Have Their Own Language
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Kernel Share Preliminary Results from Flow Feasibility Study
Via Investor Brand Network
American Billionaire Entrepreneurs Bet Millions on Psychedelics
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman... 
Via FinancialNewsMedia
U.S. Army Sued Over Discharging Soldiers with Substance-Abuse Issues
Via Investor Brand Network
Topics Lawsuit
Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Preclinical Study Findings to Be Showcased at Global Event Focused on Psychedelic-Assisted Therapy
Via Investor Brand Network
Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
From Cybin Inc.
Via Business Wire
Study Says Antidepressants Don’t Meaningfully Improve Depressed People’s Well-Being
Via Investor Brand Network
Vancouver Island University to Expand Psychedelic Mental Healthcare Program
Via Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Advancing Pipeline in Commitment to Transform Mental Health Treatment Landscape
Via Investor Brand Network
Colorado Patients Reap Benefits of Ketamine Treatments for Depression
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages
Via Investor Brand Network
Oregon to Become the First State to Legally Roll Out Psilocybin
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in... 
Via FinancialNewsMedia
Topics Derivatives ETFs
Depression Causes Lasting Physiological Alterations to Immunity Cells
Via Investor Brand Network
Three Kinds of Trauma Psychedelics Hope to Treat
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference
Via Investor Brand Network
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
From Cybin Inc.
Via Business Wire
Volume of Gray Matter May Be Useful in Treatment Planning for Mental Health Conditions
Via Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment
Via Investor Brand Network
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report... 
Via FinancialNewsMedia
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Cybin (NEO: CYBN) (NYSE American: CYBN) Pipeline Program Receives Key Patent Approval
Via Investor Brand Network
Topics Intellectual Property
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
Cybin’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study
Via Investor Brand Network
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.